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Abstract The CB2 receptor is the peripheral receptor for
cannabinoids. It is mainly expressed in immune tissues,
highlighting the possibility that the endocannabinoid sys-
tem has an immunomodulatory role. In this respect, the
CB2 receptor was shown to modulate immune cell func-
tions, both in cellulo and in animal models of inflammatory
diseases. In this regard, numerous studies have reported
that mice lacking the CB2 receptor have an exacerbated
inflammatory phenotype. This suggests that therapeutic
strategies aiming at modulating CB2 signaling could be
promising for the treatment of various inflammatory con-
ditions. Herein, we review the pharmacology of the CB2
receptor, its expression pattern, and the signaling pathways
induced by its activation. We next examine the regulation
of immune cell functions by the CB2 receptor and the
evidence obtained from primary human cells, immortalized
cell lines, and animal models of inflammation. Finally, we
discuss the possible therapies targeting the CB2 receptor
and the questions that remain to be addressed to determine
whether this receptor could be a potential target to treat
inflammatory disease.
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The psychotropic effects induced by cannabis promoted
its widespread use among the population. These effects
are mediated by a cannabinoid receptor that is mainly
expressed in the central nervous system, namely CB1.
The identification of a receptor that is selectively acti-
vated by cannabinoids suggested that the human body
synthesizes at least one natural ligand for this receptor.
This hypothesis was confirmed by the discovery of two
high-affinity ligands for the CB1 receptor: arachidonoyl-
ethanolamide (AEA) [1] and 2-arachidonoyl-glycerol (2-
AG) [2]. As these novel lipid mediators were uncovered,
a second cannabinoid receptor (CB2) was being cloned
and characterized. Its expression profile among tissues
was found to be distinct from that of CB1. It was pri-
marily found in immune cells and was initially not
detected in the brain, although this was later proven
incorrect by several studies. In light of these findings, the
CB2 receptor was postulated to be responsible for the
immunomodulatory effects of cannabinoids and endo-
cannabinoids. In the past two decades, this hypothesis
was tested in a wide array of cellular and animal models.
This article offers a comprehensive review of the evi-
dence that was gathered in these studies, with a focus on
peripheral inflammation. The CB2 receptor’s potential as
a therapeutic target in inflammatory disease is also
discussed.
Cloning of the CB2 receptor
The non-psychoactive effects of cannabinoids were ini-
tially believed to be mediated either centrally or through
their interaction with non-receptor proteins. Although
there are phytocannabinoids that exert non-psychoactive
effects without binding to CB2 receptor [e.g., cannabidiol
(CBD), cannabigerol (CBG)], discovering the latter
explained many of the peripheral effects of cannabinoids.
Munro et al. cloned the human CB2 receptor in 1993 from
the promyelocytic leukaemic cell line HL-60 [3]. To
achieve this, cells were treated with dimethylformamide
to induce granulocyte differentiation, a cDNA library was
prepared, polymerase chain reaction (PCR) was per-
formed using degenerated primers, and the amplification
products were cloned and sequenced. One of the clones
showed homology to the G-protein-coupled-receptor
(GPCR) family and was related to the CB1 receptor. The
protein encoded by this sequence was found to have 44 %
homology with the CB1 receptor. This homology
increased to 68 % when only the transmembrane portion
was considered. Binding assays showed that this receptor
had high affinity for the cannabinoid receptor ligands
WIN 55,212-2 and CP 55,940, as well as the endo-
cannabinoid AEA and the phytocannabinoid D9-THC. The
authors suggested that the previously described central
receptor be named CB1 and that this novel, peripheral
receptor be named CB2.
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A few years later, Shire et al. [4] cloned the murine
CB2 receptor from a mouse splenocyte cDNA library.
They found it to be 82 % homologous to the human CB2
receptor and to have similar affinity for the ligands
AEA, CP 55,940, and D9-THC. WIN 55,212-2, however,
bound the mouse CB2 receptor with an affinity six-fold
lower than that documented for human CB2. This was
followed by the cloning of the rat CB2 receptor by
Brown et al. [5]. The authors also compared the
sequence of their clone with those of the mouse and
human CB2 receptor and found significant differences in
protein length, although these were mainly the conse-
quence of disparities in carboxyl termini. Amino acid
conservation was highest in the transmembrane regions
of the three receptors.
In addition to binding the endocannabinoids AEA and
2-AG, the CB2 receptor binds many phytocannabinoids.
The pharmacology of endocannabinoids and that of the
CB2 receptor were rigorously reviewed in the past [6, 7].
Table 1 provides a summary of the various endocannabi-
noids and phytocannabinoids and their affinity for the
human CB2 receptor.
Available tools to study CB2 receptor functions
Pharmacological compounds
Synthetic cannabinoids, such as CP 55,940 and WIN
55,212-2, were already available when the CB2 receptor
was cloned. They were subsequently shown to be potent
CB2 ligands, but also to lack selectivity, as they activate
CB1 with comparable efficiency. In this respect, several
agonists and antagonists were rapidly developed and made
available to the scientific community. The most widely
used compounds are the agonist JWH 133, and the antag-
onists SR144528 and AM630. Still, many compounds
display good potency and selectivity towards CB2. Table 2
contains a comprehensive list of those compounds, as well
as their binding potency towards human CB2, and in some
cases, the other receptors they target.
Knockout mice
The first CB2 receptor-deficient mouse was generated by
Buckley et al. in 2000 [32]. The CNR2 gene was
Table 1 Binding of endocannabinoids and phytocannabinoids to the human CB2 receptor
Ki (nM) Model References
Endocannabinoid
AEA 371 CHO cells [8]
1940 AtT-20 cells [9]
795 Sf9 cells [10]
3500 CHO cells [10]
2-AG 949 Sf9 cells [10]
650 CHO cells [10]
Dihomo-c-LEA 857 AtT-20 cells [9]
Oleamide [100,000 HEK-293 cells [11]
NADA 12,000b Rat spleen [12]
2-AG-ether [3000a COS-7 cells [13]
Phytocannabinoid
D9-THC 34.6 CHO cells [8]
D8-THC 39.3 Mouse spleen [14]
CBN 96.3 CHO cells [8]
301 AtT-20 cells [9]
CBD 2680 CHO cells [8]
b-Caryophyllene 155 HEK293 cells [15]
Ki values were obtained in function of [
3H]CP 55,940 displacement unless indicated otherwise
NADA N-arachidonoyl-dopamine, CBN cannabinol
a [3H]HU-243
b [3H]WIN55212-2
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inactivated by homologous recombination, by replacing a
341 bp fragment of its coding sequence with the neomycin
gene. This mutation eliminated part of intracellular loop 3,
transmembrane domains 6 and 7, and the carboxyl
extremity of the receptor. Autoradiography experiments
confirmed the absence of specific binding of [3H]CP 55,940
in the spleen of CB2
-/- mice. No significant difference in
the binding of [3H]CP 55,940 between wild-type and
knockout animals was found in the brain, supporting that
CB1-receptor expression was not altered in CB2
-/- ani-
mals. The authors confirmed this by demonstrating that
knockout mice were as responsive to the psychotropic
effects of D9-THC as wild-type animals.
CB2
-/- mice display no morphological differences when
compared to their wild-type counterparts. They are normal
size and weight, are fertile, have normal litter sizes and
care for their young. However, subsequent studies by other
groups show that CB2
-/- mice develop differences at the
cellular level. In this regard, Ofeck et al. have demon-
strated that CB2
-/- mice have lower counts of osteoblast
precursors and increased numbers and activity of osteo-
clasts [33]. In consequence, these mice have a low bone
mass phenotype that worsens with age. They also present
abnormalities in the development of several T and B cell
subsets [34]. While this might impair immune homeostasis,
CB2
-/- mice fail to spontaneously develop any observable
immune disease. Therefore, they are suitable to study CB2
function and have, since, become invaluable tools in
cannabinoid research. In this respect, they have been used
to define the impact of CB2 deficiency in a variety of
inflammatory disease models, and the results of these
studies will be discussed in the section entitled CB2 acti-
vation by endocannabinoids in vivo
Antibodies
As it is the case with numerous GPCRs, CB2 protein
detection is difficult due to the lack of specificity of pri-
mary antibodies. This concept was underscored in a recent
study by Marchalant et al. [35], who showed that a com-
mercially available and widely used CB2 polyclonal
antibody is heavily cross-reactive towards other proteins.
Noteworthy, they demonstrated that some of the proteins
detected by the antibody were not membrane-bound, ruling
out the previously suggested hypothesis that the additional
bands represent glycosylation variants of the CB2 receptor.
Moreover, Graham et al. [36] compared several CB2 pri-
mary antibodies in flow cytometry experiments on human
primary leukocytes. The antibodies which they compared
generated different expression patterns between cell types.
Therefore, data regarding CB2 protein detection must be
interpreted with caution.
Table 2 CB2 agonists and antagonists
Ki (nM) Other targets References
Agonist
AM 1241 3.4 TRPA1 [16, 17]
JWH 133 3.4 TRPV1 [18, 19]
GW 405833 3.6–3.92 – [20]
JWH 015 13.8 – [8]
HU 308 22.7 – [21]
L-759,633 6.4 – [22]
L-759,656 11.8 – [22]
SER 601 6.3 – [23]
GP 1a 0.037 – [24]
GP 2a 7.6 – [24]
CB 65 3.3 – [25]
HU 210 0.061–0.52 CB1, GPR55, 5-HT2 [9, 26, 27]
CP 55,940 0.6–5.0 CB1, GPR55 [26, 28]
WIN 55, 212-2 62.3 CB1,TRPA1 [9, 17, 28]
Antagonist
SR144528 0.6–4.1 – [22, 29]
AM 630 5.6–31.2 TRPA1 [22, 30]
JTE907 35.9 – [31]
– This compound is not known to activate other receptors besides CB2
TRP transient receptor potential ion channel
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The detection of the CB2 receptor using antibodies can be
substituted, to some extent, by the alternate methods. For
example, Schmo¨le et al. [37], recently, generated a bacterial
artificial chromosome (BAC) transgenic mouse model that
expresses a green fluorescent protein (GFP) under the CB2
promoter. This mouse can be used to determine CB2
expression in mouse tissues in vitro and in situ, by several
techniques, including RT-PCR, qPCR, immunoblot, flow
cytometry, and immunofluorescence. This system, based on
GFP detection, is an alternative to the use of CB2 antibodies
on mouse tissues. It is more reliable in the sense that most
antibodies directed against GFP are specific and yield
reproducible data. However, this kind of approach cannot be
used for CB2 detection in human primary cells and tissues,
which remain problematic. A different strategy that was
evaluated by Petrov et al. involves the synthesis of fluorescent
CB2 agonists [38]. The synthesized compound showed
marked selectivity for CB2 over theCB1, 5-HT2A, and 5-HT2C
receptors. This agonist was validated as a flow cytometry
probe to detect the CB2 receptor in cells, and also to evaluate
CB2-receptor binding using fluorescence microscopy. Other
methods of detection could also be added to CB2 ligands to
use them as probes, such as biotinylation [39].
CB2 expression profiles in human and animal
tissues
Expression profile of CB2 among tissues
Upon cloning the human CB2 receptor from HL-60 cells,
Munro et al. isolated a portion of a rat homologue by PCR
[3]. They used this homologue to probe various rat tissues
and detected high CB2 receptor mRNA levels in the spleen,
but not in the liver, nasal epithelium, thymus, brain, lung,
or kidney. Cell sorting allowed the authors to associate CB2
receptor expression to the monocyte/macrophage popula-
tion of the spleen rather than T cells. Two years later,
Galie`gue et al. published the first study describing CB2
receptor expression in various human tissues and isolated
leukocyte populations [40]. The authors found high CB2
mRNA levels in tonsils, spleen, PBMC, and thymus, and
were able to detect the CB2 protein in tonsils by
immunohistochemistry using an anti-CB2 polyclonal anti-
body. They also evaluated CB2 receptor mRNA expression
in numerous human organs and found it to be absent from
most non-immune tissues, with the exception of pancreas,
lung, and uterus, which had relatively low mRNA levels.
Several reports have, since, shown that the CB2 receptor is
expressed in both male [41] and female [42, 43] repro-
ductive tissues. In this regard, the CB2 receptor exerts an
important role in the fertility of both sexes, which has
already been extensively reviewed [44–47].
The pattern of CB2 receptor expression among human
tissues is consistent between studies. More groups have
reported the presence of the CB2 receptor mRNA and
protein in the human spleen [48] and tonsils [49]. More-
over, the high level of CB2 expression in human immune
tissues was also reported in murine and rodent spleen
[37, 50–56] and thymus [37, 54].
The presence and role of the CB2 receptor in the central
nervous system have yet to be fully elucidated, and the
issue was discussed in a review article recently published
by Atwood and Mackie [57]. It was initially believed that it
was not expressed in non-immune cells of the central
nervous system, because Munro et al. did not detect CB2
receptor mRNA in any brain part when they cloned the
receptor [3], which is supported by many studies
[40, 54, 58, 59]. However, we now know that the CB2
receptor is not completely absent from the brain, since it is
expressed in microglia [60]. Still, the concept of the CB2
receptor being a second central cannabinoid receptor is up
to debate for three main reasons: (1) a study showed that
the CB2 receptor agonists JWH-015 and JWH-133 modu-
late peripheral neuron functions [61] and (2) the CB2
receptor was detected in the uninjured brain by immuno-
chemistry on numerous occasions [62–64], and (3) a recent
study found that hippocampal principal neurons express
CB2 mRNA, and that CB2-selective agonist HU-308
modulated the activity of these cells [65]. Conversely, a
study that relied on GFP detection to determine the
expression of the CB2 receptor in the murine brain showed
that the signal is located in microglia [37]. Therefore, the
lack of reliability of the antibodies that were used in
immunochemistry experiments stresses the need for more
research to expand our knowledge on the involvement of
the CB2 receptor in the central nervous system and
neuroinflammation.
In 2009, Liu et al. showed that two distinct isoforms of
the CB2 receptor exist [66]. The novel CB2 isoform was a
splicing variant of the earlier cloned receptor, and was
identified from a human neuroblastoma cDNA library.
Splicing variants were also discovered in mice and rats,
although their genomic structures and transcripts were
different from those found in humans. Furthermore, the two
human variants were found to display tissue-specific
expression patterns. While the classical CB2 isoform was
predominantly found in spleen and other immune tissues,
the novel isoform was detected in higher levels in testis and
brain regions of the reward system. The identification of
this new CB2 variant could shed some light on the con-
fusing expression patterns that were previously reported.
Finally, it underscores the possibility of a role for CB2 in
reproductive and central nervous systems that are distinct
from the immunomodulatory role of the classical CB2
isoform.
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CB2 expression in immune cells
It is well known that the CB2 receptor is widespread among
cells of the immune system. Table 3 provides the literature
associated with the expression of the CB2 receptor in
human leukocytes. Every cell type that has been investi-
gated was found to express both mRNA and protein in at
least one report. However, there is conflicting data asso-
ciated with a few cell types. For example, there is no
consensus in the literature regarding the presence of the
CB2 receptor in human neutrophils. Of note, not every
study was conducted on purified, eosinophil-depleted
neutrophils. Given that eosinophils have very abundant
amounts of CB2 receptor mRNA, a small number of eosi-
nophils among the neutrophil sample could result in a false
positive. This is consistent with the observation that CB2
levels are lower in neutrophils than in eosinophils.
As discussed in the previous section, the scientific
community should always be critical when interpreting
protein data, especially of GPCRs. A large number of
researchers have now reported expression data obtained
with commercially available antibodies, and most of them
relied on a positive control to validate their results. It was
later underscored that in the case of the CB2 receptor, a
reliable negative control is absolutely necessary to confirm
that the signal is not generated by non-specific binding of
the antibody [35, 67].
CB2 receptor signaling
The CB2 receptor was associated to the GPCR family when
it was cloned. However, the signal transduction pathways
induced by CB2 receptor activation are far less character-
ized than those of CB1. CB1 is known to inhibit adenylyl
cyclase, to modulate ion channels, and to activate numer-
ous downstream signaling events, including p38 and p42/
44 MAPK (ERK-1/2), PI3K, calcium mobilization (phos-
pholipase C/IP3), the arachidonic acid cascade, and nitric
oxide production (reviewed in [83]). A few studies have
aimed to compare the signaling events of CB1 and CB2 in a
given cell system and found some divergences between the
Table 3 CB2 receptor expression in human leukocytes
Cell types Data CB2 expression References
B cells mRNA ? [36, 40, 68, 69]
Protein ? [49, 68, 70]
Basophils mRNA ? [71]
Dendritic cells mRNA ? [56]
Protein ? [56]
Eosinophils mRNA ? [71–74]
Protein ? [74]
Mast cells mRNA ? [71]
Macrophages mRNA ? [75]
Protein ? [48, 75, 76]
Microglia mRNA ? [60]
Protein ? [60]
Monocytes mRNA ? [36, 40, 68, 75, 77, 78]
Protein ? [68, 75, 78]















T cells mRNA ? [36, 40, 68, 69]
Protein ? [49, 68, 82]
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two receptors. This section recapitulates the evidence
regarding the signaling events downstream of the CB2
receptor.
Gi/o protein coupling and adenylyl cyclase inhibition
Like the CB1, the CB2 receptor couples with Gi/o proteins.
This was established by Slipetz et al. who found that in
CB2-transfected Chinese Hamster Ovary (CHO) cells,
pretreatment with pertussis toxin (PTX) abolished the
effect of cannabinoids on forskolin-induced cAMP pro-
duction [84]. Other groups using CB2-transfected cell
models found signaling events to be PTX-sensitive, sup-
porting the involvement of Gi/o proteins [85, 86]. This
interaction was later confirmed in murine microglial cells
[87], the murine macrophage cell line J774-1 [88], the
human promyelocytic cell line HL-60 [89–91], and human
bronchial epithelial cells [92]. Since it has proven to couple
to Gi/o proteins, the impact of CB2 activation on adenylyl
cyclase activity was also investigated. As expected,
adenylyl cyclase was inhibited upon treatment of cells with
CB2 receptor agonists and/or synthetic cannabinoids,
resulting in a decrease in intracellular cAMP levels
[84, 85, 93, 94].
Potassium channels
As opposed to the CB1 receptor, the CB2 receptor does not
appear to couple to potassium channels. A study by Felder
et al. [9] investigated the possible modulation of inwardly
rectifying potassium current (Kir) channels in CB2-trans-
fected AtT-20 cells. In these cells, activation of the CB2
receptor with WIN 55,212-2 failed to have an impact on
Kir. Another study showed that in Xenopus laevis oocytes
co-expressing the CB2 receptor and G-protein-gated
inwardly rectifying potassium (GIRK) channels, WIN
55,212-2 failed to induce consistent coupling of the CB2
receptor to GIRK channels [95]. Of note, the CB1 receptor
was able to couple with GIRK channels and to modulate
agonist-induced currents in the same cellular model. This
important difference between CB1 and CB2 receptors
established CB2 as a functionally distinct receptor.
Mitogen-activated protein kinases (MAPK)
Signal transduction pathways induced by CB2 receptor
activation were first investigated in CB2-CHO cells by
Bouaboula et al. [86]. They found that upon CP 55,940
addition, adenylyl cyclase inhibition was followed by
ERK-1/2 phosphorylation. This effect was significantly
diminished by the protein kinase C (PKC) inhibitor GF
109203X, suggesting that PKC was involved in MAPK
activation. Moreover, they were able to confirm their
findings in HL-60 cells, which express the CB2 receptor.
Another group investigated MAPK activation by various
CB2 ligands in HL-60 cells and found that CP 55,940,
2-AG, and AEA increased ERK-1/2 phosphorylation [89].
This effect was blocked by the CB2 receptor antagonist
SR144528 and was stronger in cells stimulated by 2-AG
and CP 55,940 than in those treated with AEA. MAPK
activation downstream of CB2 activation was also
demonstrated in vitro in murine osteoblasts [96], in
DAUDI leukemia cells [94], murine microglia [97], and
human primary monocytes [78]. Finally, this pathway was
showed to be activated in vivo, in a mouse model of acute
experimental pancreatitis. In this model, a CB2 receptor
agonist reduced inflammation through the p38-MK2 path-
way [98].
Intracellular calcium concentrations
and phospholipase C activity
A study conducted in calf pulmonary endothelial cells
showed that CB2 activation modulates intracellular cal-
cium concentrations [99]. In this model, AEA initiated
phospholipase C (PLC) activation and inositol 1,4,5-
triphosphate (IP3) production, which led to intracellular
Ca2? release from the endoplasmic reticulum, as well as
an increase in mitochondrial Ca2?. This effect of AEA
was not mimicked by arachidonic acid (AA), was blocked
by SR144528, and was unchanged by treatment with
SR141716A, confirming the involvement of the CB2, but
not the CB1 receptor. Another group later confirmed this
in HEK-293 cells co-expressing the CB2 receptor with
chimeric Gi and Go proteins [100]. In this model, treat-
ment with CP 55,940 or other CB receptor agonists was
found to increase intracellular Ca2? levels. The phos-
pholipase C inhibitor U73122 abrogated the effect of CP
55,940 on calcium mobilization, as did thapsigargin. This
evidence shows that in these cells, CB2 receptor activa-
tion induces calcium mobilization via the PLC-IP3
signaling pathway.
In vitro studies of CB2 receptor functions
CB2 activation by endocannabinoids in vitro
The endocannabinoids 2-AG and AEA both act on various
immune cell types through CB2 receptor activation (sum-
marized in Table 4). Interestingly, there is a sharp contrast
between the anti-inflammatory effects that are triggered by
the two lipids. 2-AG was most often found to modulate
functions related to leukocyte recruitment, such as che-
mokine release, adhesion to fibronectin, and migration.
This positive regulation of immune cell recruitment by
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2-AG is the main pro-inflammatory effect of endo-
cannabinoids or cannabinoids in vitro that has been
reported. AEA, on the other hand, was found to down-
regulate leukocyte functions, such as pro-inflammatory
cytokine release and nitric oxide production. A few reports
also show increased production of the anti-inflammatory
cytokine IL-10 by cells treated with AEA. In all cases, the
involvement of the CB2 receptor was confirmed by the use
of a selective antagonist. However, it is still possible that
endocannabinoid metabolites are involved in the reported
effects. Noteworthy, this hypothesis was tested in human
eosinophils which were shown to migrate in response to
2-AG [101]. In this model, the effect of 2-AG on eosino-
phil transmigration was blocked by the pre-incubation of
cells with a CB2 receptor antagonist. However, a CB2-se-
lective agonist failed to mimic the impact of 2-AG, and its
15-LO-derived metabolites were suggested to be necessary
for eosinophils to migrate. Therefore, the successful
blockade of endocannabinoid-induced effects with a CB2
antagonist does not always rule out the possibility that
other mediators, notably endocannabinoid metabolites, are
involved as well [102]. This concept could explain why
endocannabinoids can induce both pro- and anti-inflam-
matory effects.
Table 4 CB2-mediated effects of endocannabinoids on immune cell functions
Cell type Species Endocannabinoid Effects References
Anti-inflammatory effects
Astrocytes Rat AEA ;TNF-a [103]
Dendritic cells Human AEA ; IL-6, IL-12 and IFN-a [104]
Microglia Mouse (BV-2 cell line) AEA ; Nitric oxide [105]
Mouse AEA : IL-10 [106]
: IL-10
; IL-12p70 and IL-23
[107]
Rat AEA LPS-induced nitric oxide release [108]
Neutrophils Human 2-AG ; fMLP-induced migration [79]
Splenocytes Human AEA ; Primary and secondary antibody formation [109]
T cells (not separated) Human AEA ; Cell proliferation [110]
2-AG ; SDF-1-induced migration [111]
CD4? T cells Human AEA ; IL-17, IFN-c and TNF-a [110]
CD8 ? T cells Human AEA ; IFN-c and TNF-a [110]
Human AEA ; SDF-1-induced migration [112]
Pro-inflammatory effects
B cells Human 2-AG : Migration [113]
Mouse 2-AG : Migration [114, 115]
Dendritic cells Human 2-AG : Migration [116]
Eosinophils Human 2-AG : Migration [74, 117]
Human 2-AG : Migration
: LTC4 and EXC4 synthesis
[101]
Macrophages Mouse (peritoneal) 2-AG : Zymosan phagocytosis [118]
Human
(HL-60)
2-AG : Actin polymerization
: Adhesion to fibronectin
[119]
: MCP-1 and IL-8 [120]
Microglia Mouse (BV-2 cell line) 2-AG : Migration [121]
Monocytes Human 2-AG : Adhesion to fibronectin [122]
: Migration [119]
NK cells Human 2-AG : Migration [123]
T cells Human (Jurkat) 2-AG : L- and P-selectin
: Adhesion and transmigration
[124]
TNF tumor necrosis factor, IL interleukin, IFN interferon, LPS lipopolysaccharide, fMLP formyl-Met-Leu-Phe, SDF stromal cell-derived factor,
LTC4 leukotriene C4, EXC4 eoxin C4, MCP monocyte chemoattractant protein
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CB2 activation by exogenous agonists in vitro
In contrast to endocannabinoids, CB2 receptor agonists
have only been shown to exert anti-inflammatory effects on
leukocytes, which are detailed in Table 5. Some of the
studies were performed using a non-selective cannabinoid,
but the involvement of the CB2 receptor was always con-
firmed with an antagonist. In addition to downregulating
leukocyte functions, such as cytokine release, reactive
oxygen species production and migration, CB2 agonists
limited HIV-1 expression, and replication in human mac-
rophages and microglia [75, 125].
In vivo studies of CB2 receptor functions
Impact of CB2 knockout in inflammation models
Transgenic mice have greatly contributed to our under-
standing of this receptor’s role in human disease, including
Table 5 Effects of CB2 agonists on immune cell functions
Cell type Species Agonist Effects References
Astrocytes Human WIN 55,212-2 ; Nitric oxide
; TNF-a, IL-10, MCP-1 and CCL5
[126]




Monocytes Human JWH-015 ; CCL2 and CCL3-induced migration [78]
HU-308
JWH-133
; TNF-a-induced transendothelial migration [129]




; HIV-1 replication [75]
Mouse (RAW264.7) WIN 55,212-2 ; Reactive oxygen species [131]
; Nitric oxide [132]









; b-Hexosaminidase release [135]
Microglia Human WIN 55,212-2 ; HIV-1 expression [125]
Rat JWH-015 ; LPS-induced TNF-a production
; Migration
[136]
Neutrophils Mouse JWH-133 ; MIP-2a-induced migration [137]
Human JWH-133 ; TNF-a-induced MMP-9 release [138]
Splenocytes Human D9-THC ; Primary and secondary antibody formation [109]
T cells Human D9-THC ; Th2 cytokine production [139]
Human (Jurkat) CP 55,940
WIN 55,212-2
JWH-015
; SDF-1-induced migration [140]




CD8? T cells Human JWH-015 ; SDF-1-induced migration [140]
CCL chemokine (C–C motif) ligand, NF-jB nuclear factor kappa-light-chain-enhancer of activated B cells, MMP matrix metallopeptidase, MIP
macrophage inflammatory protein, HIV human immunodeficiency virus, SOCS suppressor of cytokine signaling
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inflammatory conditions. In this regard, several models
have shown that mice that are lacking the CB2 receptor
have exacerbated inflammation (summarized in Table 6).
The effects that were usually observed in CB2
-/- animals
included increased leukocyte recruitment (often neu-
trophils) and pro-inflammatory cytokine production, which
often caused tissue damage. Conversely, one study found
CB2-deficient mice to be in better condition than the wild-
type group [142]. However, the model was cecal ligation-
induced sepsis, a condition in which efficient bacterial
clearance by the immune system is vital. The authors’
observations that the CB2
-/- group had less mortality and
less bacterial invasion was explained by the lower levels of
IL-10 in these mice, which might have led to a better
phagocytic response. Overall, these findings are consistent
with the other reports of increased immune cell functions in
the absence of the CB2 receptor.
CB2 activation by exogenous agonists in vivo
The potential of activating CB2 in vivo to treat inflammation
has been investigated in numerous studies. Two main strate-
gies are employed: (1) the administration of a CB2 receptor
agonist; and (2) the administration of an endocannabinoid
hydrolysis inhibitor to augment endocannabinoid signaling.
The administration of CB2 receptor agonists has been
performed in several inflammation models. Table 7 sum-
marizes the data that were generated with this approach. In
many instances, the chosen agonist was not CB2-selective
and targeted both cannabinoid receptors, in which case, the
involvement of CB2 was confirmed by showing that the
treatment of animals with a CB2 antagonist abrogated the
effects of the cannabinoid receptor agonist. Altogether, the
results of those studies point to the conclusion that CB2
activation improves inflammation in mice. The recruitment
of leukocytes to tissues and the production of pro-inflam-
matory cytokines and reactive oxygen species were
downregulated in various inflammation models. In the case
of atherosclerosis, two studies showed not only a decrease
in inflammatory cells and mediators upon cannabinoid
treatment, but also a slower progression of the disease
[148, 149]. Indeed, oral D9-THC administration, at doses
that are suboptimal for inducing psychotropic effects,
resulted in reduced atherosclerotic lesion development.
Since these effects of D9-THC were shown to be mediated
by the CB2 receptor, this supports that a selective CB2
receptor agonist might be a valuable tool for the treatment
of atherosclerosis.
CB2 activation by endocannabinoids in vivo
The most widely used approach to investigate the impact of
endocannabinoids in vivo is the blockade of their hydrol-
ysis, as it is an efficient way to increase their levels in
tissues. Despite the numerous studies that have used this
method in animal models, it is still unclear whether the
effects of endocannabinoids are pro- or anti-inflammatory.
This is due, in part, to the presence of numerous enzymes
that can metabolize them into other bioactive lipids. The
main pathway is hydrolysis into AA by lipases, such as
MAG lipase for 2-AG [164] and FAAH for AEA [165]. AA
is a precursor for the biosynthesis of leukotrienes, pros-
taglandins, and other lipid mediators of inflammation.
Alternatively, endocannabinoids can undergo oxidation
Table 6 Anti-inflammatory effects of CB2 receptor deletion in inflammation models
Model Species Genotype Effects References
DNFB-induced hypersensitivity Mouse CB2
-/- : Neutrophil recruitment
: Ear swelling
[143]
Hepatic ischemia–reperfusion injury Mouse CB2




TNBS-induced colitis Mouse CB2
-/- : Colitis
: TNF-a and IL-1b
[145]
Myocardial ischemia–reperfusion injury Mouse CB2
-/- : Neutrophil and macrophage infiltration
; IL-10
[146]
Traumatic brain injury Mouse CB2
-/- : TNF-a, iNOS and ICAM mRNA
: Blood–brain barrier permeability
[147]





DNFB 2,4-dinitrofluorobenzene, TNBS trinitrobenzenesulfonic acid, iNOS inducible nitric oxide synthase, ICAM intercellular adhesion molecule
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and the biological effects of the metabolites that originate
from these pathways are not very well characterized [166].
Therefore, it is not possible to conclude that endo-
cannabinoids exert their effects through CB2 in an
inflammation model unless this is confirmed by the genetic
or pharmacological blockade of the receptor. In this
respect, Table 8 only presents studies that have thoroughly
confirmed the involvement of the CB2 receptor in the
effects they observed.
A limited number of studies reported pro-inflammatory
effects of endocannabinoids in vivo, and only three of
those (listed in Table 9) were confirmed to involve the
Table 7 Anti-inflammatory effects of CB2 agonists in animal models of inflammation
Model Species Treatment Effects References








; MCP-1, IL-6 and TNF-a
[148]
Breast cancer cell injection Mouse D9-THC ; Splenocyte proliferation [150]
Brain ischemia Mouse JWH-133 ; Microglia and macrophage infiltration
; IL-6, MCP-1, MIP-1a, CCL-5 and TNF-a
; iNOS
[151]
Experimental autoimmune encephalomyelitis Mouse D9-THC
JWH-133
; Monocyte recruitment
; IFN-c and IL-2
; T cell proliferation
[152]
Hepatic ischemia–reperfusion injury Mouse D8-THCV ; Hepatic injury





Rat JWH-133 ; TNF-a
; Microglia accumulation
[154]
L. pneumophila infection Mouse D9-THC ; IFN-c and IL-12 [155]
Influenza virus infection Mouse D9-THC ; Lymphocyte and monocyte recruitment
; Viral hemagglutinin
[156]
Myocardial ischemia–reperfusion injury Mouse WIN 55,212-
2
;Myeloperoxidase





; Mast cell degranulation
; TNF-a and PGD2
[158]
LPS-induced interstitial cystitis Mouse JWH-015 ; Leukocyte infiltration
;Myeloperoxidase
; TNF-a, IL-1a and IL-1b
[159]
Sepsis Mouse HU308 ; Adherent leukocytes in submucosal
venules
[160]
Spinal cord injury Mouse O-1966 ; Leukocyte infiltration
; CXCL9 and CXCL11
; IL-23p19 and IL-23R
; TLR expression
[161]
Stress-induced neuroinflammation Mouse JWH-133 ; TNF-a and MCP-1
; COX-2, iNOS and NF-jB
[162]
Traumatic brain injury Mouse O-1966 ; Microglia and macrophage infiltration
; Blood–brain barrier disruption
[163]
PGD2 prostaglandin D2, COX-2 cyclooxygenase-2
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CB2 receptor. In two models of dermatitis in mice,
treatment with the CB2 antagonist SR144528 improved
inflammation by inhibiting granulocyte recruitment and
pro-inflammatory mediator production [174, 175]. In both
cases, this translated in a measurable decrease in swelling.
As presented above in Table 6, 2-AG has been implicated
in the recruitment and migration of B and T cells, den-
dritic cells, eosinophils, monocytes, and natural killer
cells in a CB2-dependent manner, which could very well
translate to in vivo studies. However, to this day, there is
no published data demonstrating that exogenous
cannabinoids and selective CB2 receptor agonists have
pro-inflammatory effects. Therefore, it is possible that the
pro-inflammatory effects of endocannabinoids that are
presented in Table 9 are a result of CB2 activation and/or
the action of one or more endocannabinoid metabolites
[102].
Of note, many disorders cause a change in CB2 receptor
protein levels, due to pre-existing pro-inflammatory con-
ditions. In multiple sclerosis and amyotrophic lateral
sclerosis, for instance, the expression of CB2 in microglia
is increased, both in human tissues and mouse models
[176, 177]. A similar effect was reported in a rodent model
of neuropathic pain [178]. This certainly facilitates the
impact of CB2 receptor activation by exogenous agonists of
endocannabinoids in these inflammation models.
Table 8 Anti-inflammatory effects of CB2 activation by endocannabinoids in mouse models of inflammation
Model Treatment Effects References
ConA-induced hepatitis AEA ; Inflammatory cytokines [144]
Carrageenan-induced acute inflammation URB602 ; Edema
; Nociception
[167]
Experimental autoimmune encephalomyelitis WWL70 ; iNOS, COX-2, TNF-a and IL-1b




LPS-induced acute lung injury JZL184 ; Leukocyte infiltration
; BALF cytokines and chemokines
[169]
LPS-induced inflammatory pain FAAH KO ; Edema
; TNF-a and IL-1b
[170]
FAAH KO, PF-3845, URB597 or OL-135 ; Allodynia [171]
Kaolin and carrageenan-induced osteoarthritis URB597 ; Leukocyte rolling
; Microvascular perfusion
[172]
TNBS-induced colitis JZL184 ; Submucosa edema
; Leukocyte infiltration
; Mucosal IL-6 and IL-1b
; Circulating inflammatory markers
[173]
ConA concanavalin A, BALF bronchoalveolar lavage fluid
Table 9 Pro-inflammatory effects of CB2 signaling in mouse models of inflammation
Model Treatment Effects References
Primary immunization 2-AG : Delayed-type hypersensitivity
: DC migration to draining lymph nodes
[116]




Oxazolone-induced dermatitis SR144528 ; Eosinophil recruitment
; Swelling
; MCP-1, MIP-1 and TNF-a
[175]
TPA 12-O-tetradecanoylphorbol-13-acetate
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The CB2 receptor as a potential therapeutic target
While there is a large body of evidence supporting that CB2
receptor activation has anti-inflammatory effects, it has yet
to be targeted to treat human disease. In the two previous
sections, we presented in vitro and in vivo studies that
suggested a role for the CB2 receptor in numerous
inflammatory conditions. In this section, we discuss the
potential of the CB2 receptor as a target in the treatment of
chronic inflammatory diseases, such as rheumatoid arthri-
tis, atherosclerosis, and inflammatory bowel disease.
Potential in rheumatoid arthritis
Rheumatoid arthritis (RA) is an inflammatory disease that
affects approximately 1 % of the adult population world-
wide. RA is characterized by chronic inflammation of the
synovium, cartilage destruction, and bone loss. Patients
with RA exhibit an influx of innate (neutrophils, macro-
phages) and adaptive (lymphocytes) immune cells in the
synovial cavity. These cells promote inflammation and
connective tissue damage by producing cytokines (TNF-a,
IL-6, IL-1b), pro-inflammatory lipids, and metallopro-
teinases (MMPs). The synovial lining becomes
hyperplastic and an invasive structure (the pannus) is
formed. Osteoclasts become exaggeratedly activated and
cause bone resorption [180].
2-AG and AEA are present in the synovial fluid of
patients with RA, but not healthy volunteers, suggesting an
involvement of the endocannabinoid system in the disease.
CB1 and CB2 mRNA and proteins were also found in the
synovial tissues of RA patients [181]. CB2 activation can
inhibit the production of pro-inflammatory cytokines and
MMP release from fibroblast-like synoviocytes (FLSs)
[182, 183]. It can also promote osteoblast differentiation
in vitro [33, 184] and inhibit FLS proliferation [182]. These
observations indicate that CB2 receptor activation in RA
joints could improve multiple aspects of the disease,
including inflammation, FLS hyperplasia, and bone loss.
In vivo, CB2 agonists have proven to be beneficial in a
murine model of rheumatoid arthritis, collagen-induced
arthritis (CIA). One study showed treatment with the CB2
receptor agonist JWH 133 to improve arthritis severity and
to reduce bone destruction and leukocyte infiltration in the
joints [183]. Another group investigated the impact of a
different CB2-selective agonist, HU-308. They found that
the agonist decreased swelling, synovial inflammation, and
joint destruction, in addition to lowering circulating anti-
bodies against collagen II [185]. Finally, the agonist HU-
320 ameliorated established CIA [186]. Of note, CB2
agonists did not prevent the onset of RA in any of those
reports, as there were no differences in disease incidence
between groups.
This growing body of evidence establishes the CB2
receptor as a promising target for the treatment of RA. In
all three of the above-mentioned studies, the CIA model
was used to test CB2 agonists. Given that there is no animal
model of RA that perfectly duplicates all aspects the human
condition, these findings should be confirmed in different
models.
Potential in atherosclerosis
Atherosclerosis is an inflammatory disease that is charac-
terized by the presence of arterial plaques. These lesions
contain immune cells, lipid-laden macrophages (foam
cells), cholesterol, smooth muscle cells, and collagen fibres
[187]. The physical rupture of the plaques causes the
occlusion of arteries, which can lead to tissue infarction.
Plaque development is influenced by inflammatory medi-
ators, such as cytokines and chemokines, which are crucial
to the recruitment of immune cells to the intima. In this
respect, therapies that would downregulate the production
of these mediators could reduce the progression of
atherosclerotic lesion development. Since the CB2 receptor
is known to decrease the production of numerous
chemokines and to inhibit leukocyte migration in vitro and
in vivo, it emerged as a potential target to treat
atherosclerosis.
A recent study specifically aimed to characterize the
endocannabinoid system in human foam cells [188]. The
authors found that the CB2 agonist JHW-015 significantly
decreased oxLDL accumulation in these macrophages.
Moreover, it reduced the production of TNF-a, IL-6, and
IL-10 and the expression of CD36, a scavenger receptor
that is responsible for the uptake of modified lipoproteins
by macrophages and the induction of foam cell formation.
The endocannabinoids 2-AG and AEA mimicked these
effects, which were block by the CB2 antagonist
SR144528. These findings are in accordance with a pre-
vious study which showed that CB2 activation by WIN
55,212-2 reduces the oxLDL-induced inflammatory
response in rat macrophages [131].
As briefly discussed in the section entitled In vivo
studies of CB2 receptor functions, the role of the CB2
receptor was investigated in mouse models of atheroscle-
rosis. The first study to demonstrate the benefits of CB2
activation in atherosclerosis was performed in ApoE-/-
mice using low doses of the cannabinoid D9-THC, which
diminished inflammation and blocked the progression of
the disease [149]. These effects were prevented by
SR144528, confirming the involvement of the CB2
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receptor. The anti-atherosclerotic effects of CB2 in the
ApoE-/- model were later confirmed with WIN 55,212-2
as an agonist, and the antagonist AM630 confirmed the
mechanism to be CB2-dependent [148, 189]. In Ldlr
-/--
CB2
-/- double knockout mice, lesional macrophage and
smooth muscle cell contents were higher than in
Ldlr-/-CB2
?/? animals [190]. In Ldlr-/- mice deficient for
CB2 in hematopoietic cells only, plaque area after
12 weeks on an atherogenic diet was larger than in mice
with no CB2 deficiency [191].
In summary, a large body of evidence strongly suggests
that CB2 receptor activation is an appropriate target for
atherosclerosis treatment. CB2 agonists have the potential
to be beneficial on many levels, as they were shown to
improve inflammatory cell recruitment and activation, lipid
uptake by macrophages, and the size of atherosclerotic
plaques. However, a few reports show conflicting data,
especially in the Ldlr-/- model. A report shows unaltered
lesion size following WIN 55,212-2 treatment in this
model, although CB2 receptor activation did decrease
lesional macrophage accumulation [192]. Another group
treated Ldlr-/- mice with JWH-133 and found no signifi-
cant effect on lesion size or on their content in
macrophages, lipids, smooth muscle cells, collagen, and T
cells [193]. More investigation is required to determine the
causes of these discrepancies before moving forward in the
development of therapies targeting CB2 for atherosclerosis.
Potential in inflammatory bowel disease
Inflammatory bowel disease (IBD) includes two main
conditions: ulcerative colitis and Crohn’s disease. They are
caused by an excessive immune response and can affect
any part of the gastrointestinal tract [194]. The endo-
cannabinoid system first gained interest in IBD
pathophysiology in light of a study that described a pro-
tective effect of CB1 in DNBS-induced colitis [195].
Cannabinoids were then shown to enhance epithelial
wound healing in a CB1-dependent fashion [76]. The
authors of the latter study also evaluated the expression of
cannabinoid receptors in human IBD tissue by immuno-
chemistry. They found that the CB1 receptor was expressed
in the normal human colon, but that CB2 expression was
higher in IBD tissues and that its presence was concen-
trated in plasma cells and macrophages. These findings
raised the hypothesis that the CB2 receptor was also
involved in the inflammatory component of IBD.
A subsequent study reported that a FAAH inhibitor
decreased inflammation in the TNBS-induced colitis
model, and that the deletion of either CB1 or CB2 abrogated
this effect [196]. In the same colitis model, the use of the
MAG lipase inhibitor JZL184 to increase 2-AG levels also
inhibited the development of colitis [173]. Mice treated
with JZL184 had less colon alteration and lower expression
of pro-inflammatory cytokines, and these effects were
abolished by the antagonists AM251 (CB1) and AM630
(CB2).
Several groups tested the impact of a CB2 receptor
agonist in the IBD models. The CB2-selective agonists
JWH-133 and AM1241 both protected against TNBS-in-
duced colitis, whereas AM630 worsened it [197]. The non-
psychotropic cannabinoid cannabigerol (CBG) was tested
in DNBS-induced colitis and was found to reduce the colon
weight/colon length ratio (an indirect marker of inflam-
mation), MPO activity, and iNOS expression by a CB2-
dependent mechanism [198]. Finally, the plant metabolite
and unconventional CB2 agonist (E)-b-caryophyllene
(BCP) was also evaluated in a model of DSS-induced
colitis. Oral administration of BCP decreased micro- and
macro-scopic colon damage, MPO activity, NF-jB acti-
vation, and pro-inflammatory cytokine production [199].
This wide array of CB2 receptor agonists being able to
improve IBD in animal models prompted the development
of highly selective compounds that could be used to treat
the disease in humans. In this regard, a research group
synthesized a series of CB2-selective agonists and tested
the resulting lead compounds in models of experimental
colitis [200, 201]. Intra-peritoneal injection of the agonists
was effective at protecting mice against colitis. Of note, a
selective compound that is orally effective in experimental
colitis was later synthesized [202].
Conclusion
In light of the evidence that was generated over the past
two decades by the scientific community, we can draw a
few general conclusions regarding the role of the CB2
receptor. First, it is mainly found in immune tissues and is
expressed in most immune cell types. Second, its deletion
in animals usually causes an exacerbated inflammatory
phenotype in several models, due to an upregulation of
immune cell functions. Third, CB2 activation by cannabi-
noids, either in vitro or in vivo, usually decreases
inflammatory cell activation. Finally, the administration of
CB2 agonists in animal models of inflammatory disease can
slow the progression of some diseases, in addition to
reducing inflammation.
Several questions still need to be investigated. For
example, there is no consensus regarding the expression of
the CB2 receptor in non-immune brain cells, and the role
that CB2 might play in brain functions is unknown.
Moreover, the impact of endocannabinoids on immune
cells is still unclear. While most animal studies show that
the blockade of endocannabinoid hydrolysis results in less
inflammation, it is not possible to tell whether these effects
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are caused only by CB2 activation and whether the opposite
would occur in humans. In this respect, endocannabinoids
can induce human leukocyte migration (Table 4). How-
ever, the impact of endocannabinoid metabolites on
leukocyte functions is not well defined, and this should be
addressed before endocannabinoid hydrolysis inhibitors
that can be considered as a valid strategy to enhance CB2
receptor signaling [102]. Finally, the few CB2 agonists that
are currently being developed aim at treating inflammatory
pain [203–205]. Perhaps, these novel compounds are
worthy of sparking new studies to define their putative
beneficial role in inflammatory diseases.
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